Skip to main content

Table 3 Frequencies of 22 SNPs of 3 genes in metastatic breast cancer patients with and without capecitabine-induced HFS

From: Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer

Gene

SNP 

Genotype

Patients with HFS [cases (%)]

Patients without HFS [cases (%)]

P value

Total

  

193

149

 

TYMS

rs2790

AA

78 (40.4)

48 (32.2) 

0.316

 

GA

87 (45.1)

74 (49.7)

 
 

GG

26 (13.5)

24 (16.1)

 
 

NA

2 (1.0)

3 (2.0)

 

rs15872

TT

73 (37.8)

68 (45.6)

0.265

 

TC

96 (49.7)

61 (40.9)

 
 

CC

22 (11.4)

17 (11.4)

 
 

NA

2 (1.0)

3 (2.0)

 

rs699517

TT

73 (37.8)

70 (47.0)

0.195

 

TC

97 (50.3)

61 (40.9)

 
 

CC

20 (10.4)

15 (10.1)

 
 

NA

3 (1.6)

3 (2.0)

 

rs1004474

AA

61 (31.6)

45 (30.2)

0.366

 

GA

97 (50.3)

69 (46.3)

 
 

GG

32 (16.6)

34 (22.8)

 
 

NA

3 (1.6)

1 (0.7)

 

rs2606241

GG

44 (22.8)

34 (22.8)

0.022

 

GT

113 (58.5)

69 (46.3)

 
 

TT

33 (17.1)

44 (29.5)

 
 

NA

3 (1.6)

2 (1.3)

 

rs2853741

TT

38 (19.7)

48 (32.2)

0.019

 

TC

113 (58.5)

68 (45.6)

 
 

CC

39 (20.2)

31 (20.8)

 
 

NA

3 (1.6)

2 (1.3)

 

rs3786362

TT

135 (69.9)

86 (57.7)

0.055

 

CT

48 (24.9)

53 (35.6)

 
 

CC

7 (3.6)

8 (5.4)

 
 

NA

3 (1.6)

2 (1.3)

 

rs9947507

TT

193 (100.0)

149 (100.0)

NA

rs9967368

CC

55 (28.5)

52 (34.9)

0.231

 

CG

97 (50.3)

61 (40.9)

 
 

GG

38 (19.7)

33 (22.1)

 
 

NA

3 (1.6)

3 (2.0)

 

MTHFR

rs1801131

AA

143 (74.1)

101 (67.8)

0.291

 

CA

47 (24.4)

45 (30.2)

 
 

CC

1 (0.5)

1 (0.7)

 
 

NA

2 (1.0)

2 (1.3)

 

rs1801133

TT

60 (31.1)

52 (34.9)

0.662

 

TC

99 (51.3)

69 (46.3)

 
 

CC

31 (16.1)

25 (16.8)

 
 

NA

3 (1.6)

3 (2.0)

 

rs2274976

GG

163 (84.5)

131 (87.9)

0.558

 

GA

26 (13.5)

17 (11.4)

 
 

AA

1 (0.5)

0 (0.0)

 
 

NA

3 (1.6)

1 (0.7)

 

rs3737964

GG

165 (85.5)

113 (75.8)

0.029

 

AG

25 (13.0)

33 (22.1)

 
 

NA

3 (1.6)

3 (2.0)

 

rs3753582

TT

160 (82.9)

131 (87.9)

0.389

 

GT

29 (15.0)

15 (10.1)

 
 

GG

1 (0.5)

1 (0.7)

 
 

NA

3 (1.6)

2 (1.3)

 

rs4846048

AA

165 (85.5)

115 (77.2)

0.030

 

AG

25 (13.0)

33 (22.1)

 
 

NA

3 (1.6)

1 (0.7)

 

rs4846049

GG

138 (71.5)

97 (65.1)

0.338

 

GT

49 (25.4)

49 (32.9)

 
 

TT

3 (1.6)

2 (1.3)

 
 

NA

3 (1.6)

1 (0.7)

 

RRM1

rs720106

AA

142 (73.6)

98 (65.8)

0.054

 

AG

40 (20.7)

46 (30.9)

 
 

GG

7 (3.6)

2 (1.3)

 
 

NA

4 (2.1)

3 (2.0)

 

rs725519

AA

142 (73.6)

98 (65.8)

0.532

 

AG

40 (20.7)

46 (30.9)

 
 

GG

7 (3.6)

2 (1.3)

 
 

NA

4 (2.1)

3 (2.0)

 

rs1042858

AA

116 (60.1)

78 (52.3)

0.491

 

CA

64 (33.2)

56 (37.6)

 
 

CC

10 (5.2)

9 (6.0)

 
 

NA

3 (1.6)

6 (4.0)

 

rs1042927

AA

118 (61.1)

81 (54.4)

0.415

 

CA

61 (31.6)

57 (38.3)

 
 

CC

11 (5.6)

9 (6.0)

 
 

NA

3 (1.6)

2 (1.3)

 

rs1980412

CC

61 (31.6)

58 (38.9)

0.359

 

TC

102 (52.8)

69 (46.3)

 
 

TT

26 (13.5)

19 (12.8)

 
 

NA

4 (2.1)

3 (2.0)

 

rs11030918

TT

103 (53.4)

74 (49.7)

0.378

 

CT

66 (34.2)

61 (40.9)

 
 

CC

21 (10.9)

12 (8.1)

 
 

NA

3 (1.6)

2 (1.3)

 
  1. P value < 0.05 was considered statistically significant (in italics)
  2. SNP, single nucleotide polymorphism; HFS, hand-foot syndrome; TYMS, thymidylate synthase; MTHFR, methylene tetrahydrofolate reductase; RRM1, ribonucleotide reductase M1; NA, not applicable